Transcript
Welcome to this collection of learning and assessment on the topic of liver disease.
Liver disease is currently one of the top five most common causes of death in England, mainly due to lifestyle factors such as excessive alcohol consumption, obesity and the spread of hepatitis B and C infection. However, liver disease is largely preventable and, in many cases, damage to the liver can be reversed if diagnosed early enough.
Pharmacy professionals working in all sectors can have an important role to play in supporting the management of patients with liver disease. Having an understanding of the key issues will help you to support these patients in your role.
There are two main areas where pharmacy professionals can make a difference. Firstly, patients with liver disease often present with complicating symptoms, so you are well placed to recognise symptoms and make recommendations for management. Secondly, medicines use in liver impairment is not straightforward and you can offer valuable advice on adjusting or avoiding particular medicines for patients with impaired liver function.
Completing the learning and assessment on this important topic will increase your confidence in this area, allowing you to better support patients with liver disease and use your medicines expertise to add value to the care of these patients.
The aim of this e-learning programme is to provide learners with a basic awareness of important blood tests and how to interpret them in order to support the diagnosis and management of patients. Section 1 covers full blood count, inflammatory markers and coagulation.
There are three sections which make up this learning programme. To access the other sections, select the links below:
Section 2 covers chronic disease markers, urea and electrolytes and liver function tests.
Section 3 covers thyroid function tests, bone function tests and therapeutic drug monitoring.
Please note: this e-learning programme has been developed and provided by the Welsh Centre for Pharmacy Professional Education (WCPPE). Users should recognise that this programme may refer to Welsh policies and organisations. CPPE does not maintain control over the accuracy and currency of this programme.
3h:00m (for events this includes pre and post event learning)
Learning Outcomes:
On completion of all three sections of this learning programme you should be able to:The aim of this e-learning programme is to provide learners with a basic awareness of important blood tests and how to interpret them in order to support the diagnosis and management of patients. Section 2 covers chronic disease markers, urea and electrolytes and liver function tests.
There are three sections which make up this learning programme. To access the other sections, select the links below:
Section 1 covers full blood count, inflammatory markers and coagulation.
Section 3 covers thyroid function tests, bone function tests and therapeutic drug monitoring.
Please note: this e-learning programme has been developed and provided by the Welsh Centre for Pharmacy Professional Education (WCPPE). Users should recognise that this programme may refer to Welsh policies and organisations. CPPE does not maintain control over the accuracy and currency of this programme.
3h:00m (for events this includes pre and post event learning)
Learning Outcomes:
On completion of all three sections of this learning programme you should be able to:The aim of this e-learning programme is to provide learners with a basic awareness of important blood tests and how to interpret them in order to support the diagnosis and management of patients. Section 3 covers thyroid function tests, bone function tests and therapeutic drug monitoring.
There are three sections which make up this learning programme. To access the other sections, select the links below:
Section 1 covers full blood count, inflammatory markers and coagulation.
Section 2 covers chronic disease markers, urea and electrolytes and liver function tests.
Please note: this e-learning programme has been developed and provided by the Welsh Centre for Pharmacy Professional Education (WCPPE). Users should recognise that this programme may refer to Welsh policies and organisations. CPPE does not maintain control over the accuracy and currency of this programme.
3h:00m (for events this includes pre and post event learning)
Learning Outcomes:
On completion of all three sections of this learning programme you should be able to:Medscape MELD score for end-stage liver disease (not suitable for patients under the age of 12)
British Liver Trust: facts about liver disease
NICE NG49 Non-alcoholic fatty liver disease (NAFLD): assessment and management
NICE NG50 Cirrhosis in over 16s: assessment and management
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
NICE CG100 Alcohol-use disorders: diagnosis and management of physical complications
Early palliative interventions, including reviewing regular medicines and managing common symptoms, enables patients to remain comfortable during end-of-life care.
Please help us improve our website by letting us know what you like and reporting anything that isn't quite right.